Governments and regulators must step up today to support a profession that's been pushed to its limit as we enter a new stage of the pandemic, say the Canadian Pharmacists Association.
Pfizer’s Paxlovid expected to overshadow Merck’s molnupiravir, with higher efficacy in preventing hospitalization/death in high-risk outpatients with mild/moderate COVID-19.
Half of Ontarians who died of an opioid overdose in the early stages of the pandemic had interacted with the healthcare system in the month before their deaths, a new report shows.
The authorization says the treatment is greenlit for adult patients with mild or moderate COVID-19 who are also at high risk of becoming more seriously ill.